Neurocrine Biosciences, Inc. (NBIX)
| Market Cap | 10.29B |
| Revenue (ttm) | 1.05B |
| Net Income (ttm) | 407.30M |
| Shares Out | 93.10M |
| EPS (ttm) | 4.16 |
| PE Ratio | 26.32 |
| Forward PE | 35.71 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $109.51 |
| Previous Close | $106.81 |
| Change ($) | 2.70 |
| Change (%) | 2.53% |
| Day's Open | 108.00 |
| Day's Range | 105.58 - 110.58 |
| Day's Volume | 1,292,558 |
| 52-Week Range | 72.14 - 136.26 |
Neurocrine (NBIX) delivered earnings and revenue surprises of 506.78% and -4.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Neurocrine Biosciences (NASDAQ:NBIX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 13.33% year over year to $0.91...
SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full-year ended December 31, 2020 and provi...
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq mar...
Our theme of Out Of Favor Health Care Stocks includes health care stocks that have witnessed strong Revenue growth and improving fundamentals over the last few years but have underperformed in...
SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product and inventory adjust...
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on Monday Jan. 1...
After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.
Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, has more room for growth in the near term. NBIX stock is...
Neurocrine Biosciences reported disappointing sales of Ingrezza, as disruptions to clinical practice caused by COVID-19 have impacted new prescriptions, refills, and patient compliance. If COV...
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2020 Results - Earnings Call Transcript
Neurocrine (NBIX) delivered earnings and revenue surprises of -663.64% and -8.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Neurocrine Biosciences (NASDAQ:NBIX) decreased 13.34% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 7.78% year over year...
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2020 and provided revised fu...
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: K...
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another...
Our indicative theme of Out Of Favor Healthcare Stocks Poised For Gains is down by about -13% year-to-date, compared to the S&P 500 which is up by about 2% over the same period. This theme inc...
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.
Investors seeking strong growth companies to invest in should watch Credit Acceptance Corporation, RenaissanceRe and Neurocrine Biosciences. The post 3 Companies to Invest In for Mammoth Growt...
Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma co...
With earnings season about to kick off, investors are being forced into a different sort of earnings season.
SAN DIEGO and BOSTON, Oct. 7, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Boston-based Me2/Orchestra, the world's only known classical music organization created for p...
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results
SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday...
SAN DIEGO, Sept. 28, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data analyses evaluating the efficacy and safety of ONGENTYS® (opicapone) ...
Ongentys, an add-on treatment for patients with Parkinson's disease, is entering the market soon.
Neurocrine Presents Data, And Other News: The Good, Bad And Ugly Of Biopharma
Neurocrine Looks Like A Long-Term Value After Share Price Decline
New Data Support The Idea That Neurocrine Biosciences Is Building A Credible Parkinson's Portfolio
The much-anticipated launch of Ongentys has arrived.
SAN DIEGO, Sept. 14, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.
Three years after treatment with NBIb-1817, Parkinson's disease patients still are still showing improvements.
SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.
SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.
SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.
SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc.
Ingrezza Remains Surprisingly Strong For Neurocrine
The biotech blew past Wall Street estimates with soaring sales of Ingrezza.
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q2 2020 Results - Earnings Call Transcript
Neurocrine (NBIX) delivered earnings and revenue surprises of 24.62% and 18.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Late Monday, Neurocrine Biosciences reported second-quarter earnings that doubled the year-earlier figure, shattering analyst expectations and sending shares of NBIX stock higher after hours. ...
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These frontrunners are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of the opportunity.
Health-care stocks keep hitting highs. Mark Newton of Newton Advisors and Danielle Shay of Simpler Trading share their favorite names.
SAN DIEGO, July 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Mond...
Neurocrine Further Expands Its Pipeline With An Early-Stage Deal
During a May 6 earnings conference call, the head of business development and strategy for Neurocrine Biosciences Inc (NASDAQ:NBIX) said the company was looking for other partnerships, similar...
The 2020 year is practically halfway done, and this has really been the year of the biotech.
Neurocrine's full Phase II data presentation on crinecerfont in adult patients with CAH didn't have many surprises, but the positive efficacy and safety data were welcome.
About NBIX
Neurocrine Biosciences, a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treat... [Read more...]
| Industry Biotechnology | IPO Date May 23, 1996 |
| CEO Kevin Gorman | Employees 845 |
| Stock Exchange NASDAQ | Ticker Symbol NBIX |
Financial Performance
In 2020, NBIX's revenue was $1.05 billion, an increase of 32.71% compared to the previous year's $788.10 million. Earnings were $407.30 million, an increase of 1,000.81%.
Analyst Forecasts
According to 25 analysts, the average rating for NBIX stock is "Buy." The 12-month stock price forecast is 129.00, which is an increase of 17.80% from the latest price.